Actual combinations of herbal remedies and conventional medicines used in the clinic have been identified to a certain extent in the general population. In Canada, potential adverse herb-drug interactions were identified in 28.4% of 1062 patients using herbs and conventional medicine concurrently, corresponding to 1.4% of the total adult population. 5 Similarly, Bush et al 6 identified 85 potential adverse interactions among 122 patients using herbal remedies and Elmer et al 7 found herb-drug combinations with significant risk for adverse reactions in 5.8% of 5052 CAM using patients.
In the cancer population similar studies are less frequent. However, Malekzadeh et al 8 identified 7 herbal remedies with potential to interact with drugs used by a population of 233 breast cancer patients. Recently, Eschiti 9 concluded that future research should focus on CAM therapy and drug interactions in specific groups that carry a high risk of clinically significant interactions. This survey thus aims to identify the occurrence of herbchemotherapeutic drug combinations in a group of cancer patients in Norway and to explore possible clinical consequences of these combinations.
Methods
This survey adds new data to a patient population studied earlier, with respect to herbal use during palliative A high and increasing tendency for use of complementary and alternative medicine (CAM), including herbal remedies, is seen in the population as a whole 1 and especially among cancer patients. 2 Since herbal use gives possibilities for unwanted interactions with conventional medicines, such as cytotoxic cancer drugs, awareness of possible herb-drug interactions is important.
Case reports and clinical studies have verified that herbal remedies contribute to herb-drug interactions. St. John's wort, one of the most intensively studied herbal remedies, induces the metabolism of oral contraceptives. This may lead to breakthrough bleeding and unwanted pregnancies. 3 St. John's wort also reduces the plasma concentration of cyclosporine in renal transplant patients. 4 Pharmacokinetic interactions as these are often caused by herbal induction or inhibition of the drug metabolizing enzyme system cytochrome P-450 (CYP) and/or the P-glycoprotein (P-gp) drug efflux transport system.
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Keywords: medicinal herbs; chemotherapy; herb-drug interactions; cytochrome P-450; p-glycoprotein and curative therapy. 10 The present study is performed as a cross-sectional descriptive survey. Cancer patients 18 years or older were included. All were currently undergoing cytotoxic chemotherapy treatment at 2 outpatient clinics in a rural area on the west coast of central Norway in the period between March 2006 to March 2007.
The survey was approved by the Regional Committee for Research Ethics, Central Norway and by the Norwegian Social Science Data Services. All patients were given oral and written survey information and signed a written consent for participation.
All patients were presented a predefined list of 19 herbal remedies (Table 1 ) of both botanical and animal origin. 11 The patients could list as many herbs as needed. The list was designed to represent a variety of herbal remedies, including those reportedly used by cancer patients in general and those traditionally used by the Norwegian population. Concurrent users were defined as patients having used or presently using herbal remedies concurrent with chemotherapy treatment. Nonconcurrent users were defined as patients that had never used herbal remedies or that stopped using herbal remedies before starting chemotherapy treatment. Questions about adverse effects were requested from all herbal users. Information on the individual patients' diagnosis and treatment regime was gathered.
The herb-drug combinations found in the patient group were registered as 2-agent combinations: 1 herbal remedy and 1 chemotherapeutic agent. The chemotherapeutics were grouped according to the Anatomical, Therapeutic, Chemical (ATC) Classification System. Assessment of potential pharmacokinetic herb-drug interactions among the identified combinations was based on clinical evidences and reported abilities of both herbs and drugs to interfere with CYP metabolism and/or P-gp transport. Information on this was obtained from recent reviews and from a systematic search in the databases Medline (Pubmed), EMBASE, and the Cochrane Library for primary literature.
Statistics
SPSS 13.0 (SPSS, Chicago, Illinois) was used for statistical analysis. Fisher-Freeman-Halton's exact test was, because of small samples, used to assess differences between nonconcurrent and concurrent users. Two-sided P values < .05 were defined as statistically significant.
Results
The results of this survey are based on 112 eligible patients (response rate, 78%). Of these, 42 were identified as concurrent users. Demographic data for all participants are presented in detail elsewhere. 10 Briefly, men and women were evenly distributed in the group of concurrent users (21 men, 21 women) and 33 (79%) of these patients were older than 50 years (range, 31-77).
Nonconcurrent and concurrent users were not statistically different according to the Fisher-Freeman-Halton's exact test when comparing diagnostic groups and numbers of chemotherapeutics used with respect to herbal use (P = .13 and P = .75, respectively). Herbal remedies were used daily by 29 of the concurrent users (69%) and the median number of herbal remedies used per patient was 2. Only 1 patient in the group of concurrent users reported to have experienced any adverse effects attributed with the intake of herbal remedies.
In Table 2 , the number of 2-agent herb-chemotherapeutic drug combinations identified among the 42 concurrent users is shown. A total of 101 different combinations were found. In total, 136 combinations were used by the patient group, giving a mean of 3.2 (median, 2; range, 1-12) combinations per concurrent using patient. Among the 23 herbal remedies reportedly used, garlic (13), green tea (11), ginger (10), and noni juice (9) were most often identified in herb-drug combinations. Among the 11 chemotherapeutic groups presented, pyrimidine analogues such as fluorouracil and gemcitabine, and platinum compounds such as carboplatin and oxaliplatin, were most frequently registered to participate in herbdrug combinations, 25 and 19, respectively.
For 48% of the herbal remedies identified in our patient material, no data existed in the literature on L) . The probability for possible pharmacokinetic herbdrug interactions could consequently be explored for only 12 out of 23 herbal remedies identified in the group of concurrent users. Green tea, garlic, echinacea, valerian, and soy were most extensively studied, while less than 4 relevant publications were found for ginger, aloe vera, agaricus, golden root, mistletoe, noni juice, and rooibos (Aspalathus linearis Dahlgren). Table 3 shows the 27 different specific 2-agent combinations identified in our patient material and available literature information. It should be noticed that each of the 2-agent combinations often involves more than 1 site of interaction; green tea may, for instance, interact with vinorelbine both at the site of CYP3A4 metabolism and at the site of P-gp transport. Some combinations are present in more than 1 patient as seen for cyclophosphamide and green tea (3) . Some patients used more than 1 combination (not shown in the table). All together in Table 3 , there were as many as 47 different possibilities for specific herb-chemotherapeutic drug interactions at different interaction sites identified.
Discussion
Results from this survey showed that among a population of 112 cancer patients 42 were using herbal remedies concurrently with chemotherapy. In the latter group, there were 136 registered 2-agent herb-drug combinations, giving a mean of 3.2 herb-drug combinations per patient. Garlic, green tea, ginger, and noni juice were the herbal remedies most frequently used in combinations with chemotherapeutic drugs. For 48% of the herbal remedies identified in our patient material, no data were available in the literature to explore possible pharmacokinetic interactions.
Compared to similar surveys 5,6,8 our population had a relatively high prevalence of herbal use and each patient used a large number of herbal remedies. However, the high percentage of theoretically possible herb-drug interactions found in our study was not unexpected. Although Bush et al 6 found the prevalence of use to be lower than that among our patients, the percentage of theoretically possible adverse interactions was found to be higher. This is explained in large by the fact that Bush et al 6 included both pharmacokinetic and pharmacodynamic interactions in their survey while we explored only possible pharmacokinetic interactions involving CYP metabolism and/ or P-gp transport.
The literature search performed for data on CYP and P-gp interactions of the herbal remedies used in our patient material revealed an alarming lack of relevant studies. Few clinical trials were located and only one of these was specific for any of the herb-chemotherapeutic drug combinations actually identified in this survey. 34 Therefore, based on the available literature, the herbal remedies could be organized in 3 groups: (1) those with relevant in vitro and clinical studies as garlic, green tea, and echinacea; (2) those with a few relevant in vitro and no clinical studies as ginger, aloe vera, and agaricus; and (3) those with no relevant studies at all as bilberries and fenugreek seeds. Hence, the herb-drug interactions included in Table 3 are based mainly on in vitro experiments alone or in combination with animal studies.
For several herbal remedies the reported in vitro interaction potentials toward CYP or P-gp are conflicting. Ginger, for instance, shows both a strong induction 29 and inhibition 26 of CYP3A4. The opposing results can probably be accounted for by differences in applied herbal concentrations, 0.1 mg/ml versus 25 mg/ml, respectively, or by lack of standardization of the herbal extracts tested, both with respect to the herbal products as such, or to the extraction methods used. 19, 22 In vitro studies should be regarded as indicative only for herbal interaction potentials toward CYP metabolism or P-gp transport and less suitable for exploring the degree of clinical relevance of identified herb-drug combinations.
Clinical studies on the herbal influence on CYP metabolism or P-gp transport have been performed on 4 of the herbal remedies found in our patient material: green tea, 35, 36 valerian, 37,38 garlic, 34, 39, 40 and echinacea. 41, 42 Four weeks of daily treatments with epigallocatechin gallate (EGCG), the main constituent of green tea, gave no significant change in CYP1A2 or 2D6 activities and x 2D6 13 x x 2E1 13, 14 x 3A4 12, 14 x x x x x x P-gp 15 x x x x Garlic 1 1 1 3 1 1 2C9 16 x 3A4 16, 17 x x x x x x P-gp 16 x x x x x Echinacea 1 1 2C9 18 x 2C19 19 x 3A4 [19] [20] [21] x P-gp 20 x Valerian 1 3A4 [22] [23] [24] x P-gp 20, 22 x Soy 1 1 2C9 25 x 3A4 [25] [26] [27] x P-gp 28 x Ginger 1 1 1 1 3A4 29, 30 x x x P-gp 29 x x Golden root 1 2C19 31 x 3A4 31 x Aloe Vera 2 3A4 29 x P-gp 29 x Mistletoe 1 P-gp 32 x Agaricus 1 P-gp 32 x Rooibos 1 3A4 33 x NOTE: Possible CYP and P-gp interaction sites (identified by in vitro studies) are given. The number of patients using a particular combination are listed.
only minor inhibitory effects on CYP3A4 35 in humans. Whether the constituent EGCG is representative for the whole herb may be questionable. Similarly, 14 days of daily treatments of a decaffeinated green tea extract did not alter the pharmacokinetics of alprazolam (CYP3A4 substrate) or dextromethorphan (CYP2D6 substrate) 36 in humans. No clinical trials have, however, been performed on the effect of whole green tea extracts on any of the CYP enzymes or P-gp. Two clinical pharmacokinetic interaction studies have been performed with valerian. One "cocktail" interaction study lasting 28 days showed that valerian did not alter the metabolism of midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), chlorzoxazone (CYP2E1 substrate), or debrisoquine (CYP2D6 substrate) 37 in humans. Similarly, the metabolism of dextromethorphan (CYP2D6 substrate) and alprazolam (CYP3A4 substrate) were not altered in humans with 14 days dosing with valerian. 38 No clinical trials have been performed for the effect of valerian on the P-gp transporter.
The clinical pharmacokinetic interaction studies performed for both green tea and valerian may indicate that the CYP interaction sites identified in vitro for these herbs in Table 3 are of minor clinical significance. However, no clinical trials have yet been performed on effects of the 2 herbs on P-gp transport.
Two clinical pharmacokinetic interaction studies have shown that garlic consumption by healthy participants and by breast cancer patients twice daily for 14 and 12 days, respectively, did not change the pharmacokinetics of the 2 CYP3A4 substrates alprazolam 40 and docetaxel, 34 respectively. In contrast, the coadministration in humans of garlic twice daily with saquinavir (P-gp substrate), for 2 days, reduced the mean saquinavir area under the curve (AUC 8 ) by 51%. 39 Thus, garlic seems to possess a clinically relevant induction potential on P-gp transport, but not on CYP3A4 metabolism. No clinical trials have been performed for the effects of garlic on CYP2C9 metabolism.
In a clinical pharmacokinetic cocktail interaction study in humans, Gorski et al, 42 echinacea, given 4 times daily for 8 days, reduced the oral clearance of caffeine (CYP1A2 substrate) by 26% and of tolbutamide (CYP2C9 substrate) by 11%, but did not effect the oral clearance of dextromethorphan (CYP2D6 substrate). Gorski et al 42 further showed that echinacea selectively inhibited hepatic CYP3A4 activity and induced intestinal CYP3A4 activity. Gurley et al, 43 however, could not confirm these results. Thus, no conclusions at present can be drawn for echinacea and possible clinically relevant interactions with CYP enzymes. No clinical trials have been preformed with echinacea on CYP2C19 metabolism or P-gp transport.
In our survey, 1 herbal remedy was of special interest. Mistletoe was reported to cause nausea, fever, and headache by 1 patient. The discomfort disappeared when reducing the dose of mistletoe. However, a pharmacokinetic interaction was unlikely since the chemotherapeutic drugs the patient received; bevacizumab, fluorouracil, and oxaliplatin, are not known CYP or P-gp substrates. 44, 45 The discomfort reported by the patient was probably because of adverse effects of mistletoe itself. 46 The large number of herb-chemotherapeutic drug combinations observed and the scarce scientific knowledge of their interaction potential is alarming considering that most chemotherapeutic drugs have narrow therapeutic indices. Lack of reported adverse effects does not automatically imply that no interactions are present in cancer populations. Since most treatments with chemotherapeutic drugs are known to have severe adverse effects, distinguishing between adverse effects caused by the chemotherapy and adverse effects caused or amplified by herb-drug interactions are difficult to separate. In addition, herb-drug interactions may manifest themselves as lack of treatment response and since many cancer treatments have low expectations of outcome, lack of treatment response is seldom linked to possible herb-drug interactions. More research is thus still needed for possible herb-chemotherapeutic drug interactions for cancer patients.
